HLA-DRA anticorps

N° du produit ABIN4910689

Cet anticorps Souris Monoclonal détecte spécifiquement HLA-DRA dans WB. Il présente une réactivité envers Humain.

Aperçu rapide pour HLA-DRA anticorps (ABIN4910689)

Antigène: HLA-DRA (HLA Class II DR alpha (HLA-DRA))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp HLA-DRA est non-conjugé

Application: Western Blotting (WB)

Clone: 30C2

Détail du produit anti-HLA-DRA anticorps

Réactivité croisée: Humain

Purification: Mouse monoclonal antibody supplied in crude ascites with 0.09% (W/V) sodium azide.

Immunogène: This HLA-DRA antibody is generated from mice immunized with a KLH conjugated synthetic peptide between 48-75 amino acids from human HLA-DRA.

Isotype: IgM

Information d'application

Indications d'application: WB 1:300-5000

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 0.5 μg/μL

Buffer: 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Store at -20°C for 12 months.

Date de péremption: 12 months

Détails sur HLA-DRA

Antigène: HLA-DRA (HLA Class II DR alpha (HLA-DRA))

Autre désignation: HLA-DRA

Sujet:

Synonyms: HLA-DRA1, HLA class II histocompatibility antigen, DR alpha chain, MHC class II antigen DRA, HLA-DRA

Background: Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface.

ID gène: 3122

UniProt: P01903

Pathways: TCR Signaling, CXCR4-mediated Signaling Events, Human Leukocyte Antigen (HLA) in Adaptive Immune Response